scispace - formally typeset
D

David M. Hwang

Researcher at Sunnybrook Health Sciences Centre

Publications -  184
Citations -  9146

David M. Hwang is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Lung transplantation & Lung. The author has an hindex of 48, co-authored 179 publications receiving 7241 citations. Previous affiliations of David M. Hwang include Toronto General Hospital & University Health Network.

Papers
More filters
Journal ArticleDOI

Normothermic Ex Vivo Perfusion Prevents Lung Injury Compared to Extended Cold Preservation for Transplantation

TL;DR: The maintenance of integrity of barrier function during EVLP translates into significant attenuation of reperfusion injury and improved graft performance after transplantation, and prevents ongoing injury associated with prolonged ischemia and accelerates lung recovery.
Journal ArticleDOI

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

TL;DR: It is discovered that changes in pathophysiology associated with tumor volume can selectively change tumor uptake of nanoparticles of varying size, and this finding presents a paradigm shift in nanomedicine away from identifying and using a universal nanoparticle design for cancer detection and treatment.
Journal ArticleDOI

The Integrated Genomic Landscape of Thymic Epithelial Tumors

Milan Radovich, +186 more
- 12 Feb 2018 - 
TL;DR: A molecular link between thymoma and the autoimmune disease myasthenia gravis is identified, characterized by tumoral overexpression of muscle autoantigens, and increased aneuploidy.
Journal ArticleDOI

Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis

TL;DR: In this paper, the authors found that pleuroparenchymal fibroelastosis is a major histopathologic correlate of restrictive allograft syndrome, and was often found concurrently with diffuse alveolar damage.
Journal ArticleDOI

PD-L1 Testing for Lung Cancer in 2019 : Perspective From the IASLC Pathology Committee

TL;DR: Although PD-L1 IHC test is now deployed in the most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging due to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided.